Metabolon Receives CLIA Certificate of Registration
RESEARCH TRIANGLE PARK, N.C. (March 17, 2011) — Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announces the receipt of a Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA) for its new facility on Davis Drive in Research Triangle Park, NC. The CLIA registration allows Metabolon’s clinical laboratory to perform high-complexity tests on patient samples. Later this year, the company plans to launch tests for insulin resistance and urological cancers based upon biochemical biomarkers the company discovered using its proprietary metabolomic profiling technology platform.
John Ryals, Metabolon’s president and chief executive officer said, “CLIA certification is an important step in our strategy to derive further economic value from our sophisticated approach to biomarker discovery while advancing our plans to fulfill the promise of personalized medicine.”
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske email@example.com at (919) 595-2200.
Lippert/Heilshorn & Assoc.